Innocan Pharma to Present at the 2025 ThinkEquity Conference

HERZLIYA, Israel and CALGARY, AB, Oct. 24, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it will be participating in The ThinkEquity Conference, taking place October 30, 2025, at the Mandarin Oriental, New York City.

The ThinkEquity Conference convenes institutional investors, analysts, and emerging growth companies for a day of presentations and one-on-one meetings, providing a valuable platform to share business updates and explore new market opportunities. 
During the conference, Innocan Pharma will be presented at 9:30 a.m. (New York time) in the Boardroom. The Company will outline its upcoming regulatory milestones across both Human and Animal Health, focusing on its LPT-CBD innovative injectable platform for chronic pain management.

Innocan's presenters will include Iris Bincovich, CEO, Roni Kamhi, COO and Innocan's distinguished advisory board member Dr. Joseph V. Pergolizzi, Jr., M.D, an expert in internal, perioperative and pain medicine, critical and palliative care, pharmacology, drug development and regulatory affairs.

For more information about the ThinkEquity Conference, please visit www.think-equity.com.

About Dr. Joseph V. Pergolizzi, Jr., M.D
Dr. Pergolizzi is a Senior Partner at Naples Anesthesia and Pain Associates and serves as the Chief Operating Officer at NEMA Research Inc. He is a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics and a consultant to the National Pain Foundation Board of Directors. He has held various C-level positions in private and public companies and can leverage his significant medical expertise, regulatory experience, and business skills to build a strong track record of success in many fields in the healthcare industry.

About ThinkEquity
ThinkEquity is a boutique investment bank founded by professionals who have collaborated for over a decade, collectively financing over US $50 billion in public and private capital raises, restructurings, and mergers and acquisitions. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect. To register to attend The ThinkEquity Conference, please follow this link.

About Innocan 
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. www.innocanpharma.com 

For further information, please contact: 
Innocan Pharma Corporation: 
Iris Bincovich, CEO 
+1 5162104025 
+972-54-3012842 
+442037699377 
info@innocanpharma.com 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. For example, the Company is using forward-looking statements when it discusses its planned participation at The ThinkEquity Conference, the potential of the Company's LPT-CBD technology as an innovative solution for pain management in patients and the achievement of regulatory milestones. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg